Newsletter Current page: 2

In December 2023, the Federal Institute for Drugs and Medical Devices (BfArM) extended the reimbursement of Selfapy’s online course for generalised anxiety disorder to men. The BfArM thus confirms the results of additional real-world evidence (RWE), which shows that Selfapy’s product also significantly reduces anxiety symptoms and improves health-related quality of life in men with […]

At the end of 2023, the SHS portfolio company TRI received the SEF Growth High Potential Label from the Swiss Economic Forum. Founded in 2011, TRI began its journey with the goal of improving patient experience and outcomes with an innovative, digitalised approach to dental implantations. With TRI’s patented matrix implant technology – the world’s […]

Dr.Dropin opened its first clinic in Oslo, Norway, in 2017. The company now has over 25 clinics in Norway and Sweden, covering general medicine, dermatology, gynaecology, psychology and physiotherapy. The first clinic in the UK, located in London, Fulham, was opened at the end of 2023. The aim is to offer high-quality, personalised and easily […]

Mr Eisen, what exactly Blue Ocean Spine is focusing on and what milestones have you achieved in the development of your technology in recent years? Our aim is to improve the function and performance of existing products through the smart use of modern development and production technologies, while at the same time reducing manufacturing costs. […]

SHS presents itself in a new look since the beginning of this year. The last years at SHS have been characterised by great developments with a clear strategy for the future. And this also raised the question of how we want to communicate our identity, our development and our vision for the future to the […]

Our investors, portfolio representatives, SHS senior advisors and healthcare experts were invited to the Hotel Krone in the centre of Tübingen. The day offered exciting presentations on healthcare investments and outlooks on economic developments and medical innovations in the coming years. Furthermore, four of the SHS portfolio companies gave exciting presentations about their companies and […]

Another format that SHS has specifically created for its portfolio companies is the SHS portfolio workshops. These take place quarterly, covering various topics. The aim is to discuss topics that concern a large proportion of the portfolio companies and to provide the companies the opportunity to exchange ideas and knowledge, to discuss approaches to solving […]

The new training and networking format is created for newer employees as well as current and former interns and is intended to provide practical insights into selected topics from the private equity industry. Speakers are both external and experienced SHS colleagues. For the first session, SHS managed to secure Sebastian Schreiber from SySS as external […]

Guillaume Balz joined the SHS team as Investment Manager in January 2023. After obtaining his Bachelor’s degree in Business and Economics in Dortmund and Athens, he completed his Master’s degree in Finance and Strategic Management in Copenhagen. He then decided to join Simon-Kucher, where he advised companies on marketing, sales, pricing and go-to-market. From the […]

Salvia BioElectronics, a pioneering Dutch company specialising in the treatment and cure of severe migraines, announced the successful first implantation of its paper-thin neuromodulation solution. Migraine is the most common cause of disability in people under 50 and affects one in seven people, mainly women. More than five percent of migraine patients suffer from chronic […]

French company PathoQuest has entered into a strategic partnership with Oxford Nanopore Technologies to bring to market the first sequencing-based quality control test for the genetic characterisation of biopharmaceuticals. Most biologics are produced using genetically modified cell lines. For many cell therapies, the product itself is a genetically modified cell line. Throughout the development of […]

You joined SHS this February to support the team in its market activities, especially in the areas of business development, communication and deal-sourcing. What was your motivation to work for SHS? With over 35 years of professional experience in M&A consulting and private equity, I have built a very extensive network of contacts and enjoy […]